Avedro Inc is a United States-based company. The Company is an ophthalmic pharmaceutical and medical device company developing and commercializing a suite of products based on its corneal collagen cross-linking technology platform to address a wide variety of ophthalmic disorders and conditions, primarily associated with corneal weakness. Its primary components of the Avedro Cross-Linking Platform are pharmaceutical formulations of riboflavin (vitamin B2), a â€˜single dose pharmaceutical,â€™ sold primarily in conjunction with the Companyâ€™s innovative devices for the delivery of metered doses of ultraviolet (UVA) light, a medical device.

Employees

Sector

Medical Equipment, Supplies & Distribution

More about the company

Delayed Nasdaq Other stock markets			5-day change	1st Jan Change
- ^USD	-.--%		+0.61%	-

22/11/19	Avedro, Inc.(NasdaqGM:AVDR) dropped from S&P TMI Index	CI
21/11/19	Avedro, Inc. Announces Board Changes	CI

22/11/19	Avedro, Inc.(NasdaqGM:AVDR) dropped from S&P TMI Index	CI
21/11/19	Avedro, Inc. Announces Board Changes	CI
21/11/19	Avedro, Inc.(NasdaqGM:AVDR) dropped from NASDAQ Composite Index	CI
21/11/19	Glaukos Corporation completed the acquisition of Avedro, Inc. from a group of sellers.	CI
06/11/19	Avedro, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019	CI
13/08/19	Certain Common Stock of Avedro, Inc. are subject to a Lock-Up Agreement Ending on 13-AUG-2019.	CI
13/08/19	Certain Options of Avedro, Inc. are subject to a Lock-Up Agreement Ending on 13-AUG-2019.	CI
13/08/19	Certain Warrants of Avedro, Inc. are subject to a Lock-Up Agreement Ending on 13-AUG-2019.	CI
13/08/19	Certain Restricted Stock Units of Avedro, Inc. are subject to a Lock-Up Agreement Ending on 13-AUG-2019.	CI
08/08/19	Avedro, Inc. Announces Resignation of Thomas W. Burns and Gilbert H. Kliman from the Board of Directors	CI
08/08/19	Avedro, Inc. Announces Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2019; Revises Revenue Guidance for the Full Year of Fiscal 2019	CI
07/08/19	Glaukos Corporation entered into a definitive merger agreement to acquire Avedro, Inc. from a group of sellers for approximately $490 million.	CI
28/06/19	Avedro, Inc.(NasdaqGM:AVDR) added to Russell 2000 Dynamic Index	CI

09/09/20	INVESTIGATION ALERT: Nationally Ranked Litigation Firm Labaton Sucharow Announces Investigation of the Merger of Avedro, Inc. and Glaukos Corporation and Strongly Encourages Investors to Contact the Firm	BU
08/09/20	INVESTIGATION ALERT: Nationally Ranked Litigation Firm Labaton Sucharow Announces Investigation of the Merger of Avedro, Inc. and Glaukos Corporation and Strongly Encourages Investors to Contact the Firm	BU
21/11/19	AVEDRO INC : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
18/11/19	AVEDRO INC : Change in Directors or Principal Officers, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
06/11/19	Avedro, Inc. Announces Third Quarter 2019 Financial Results	GL

Manager	Title	Age	Since
Thomas Griffin DFI	Director of Finance/CFO	62	01/03/2017
Desmond Adler CTO	Chief Tech/Sci/R&D Officer	-	-
Sujal Bhalakia COO	Chief Operating Officer	-	-

Avedro, Inc. Stock

Stocks

AVDR

US05355N1090

Medical Equipment, Supplies & Distribution

Latest news : Avedro, Inc.

Press Releases: Avedro, Inc.

Managers and Directors: Avedro, Inc.

Other Medical Equipment, Supplies & Distribution

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
AVEDRO, INC.	-.--%	+0.61%	-	-	403M
ABBOTT LABORATORIES	-0.10%	+0.26%	-33.52%	-17.14%	154B
MEDTRONIC PLC	+1.54%	-1.07%	-8.11%	-10.79%	102B
HOYA CORPORATION	-4.45%	+3.12%	+61.36%	+57.49%	56.51B
CENCORA, INC.	-1.90%	-3.49%	-7.43%	+47.34%	52.89B
BECTON, DICKINSON AND COMPANY	+1.67%	-1.55%	-14.51%	-43.86%	39.67B
MEDLINE INC.	-1.32%	-1.83%	-	-	30.39B
DEXCOM, INC.	+1.74%	-3.85%	-9.41%	-44.24%	27.96B
WEST PHARMACEUTICAL SERVICES, INC.	+1.35%	-0.26%	+51.96%	-10.42%	23.17B
TERUMO CORPORATION	-1.53%	+1.14%	-15.21%	-5.72%	20.35B
Average	-0.30%	-1.11%	+3.14%	-3.42%	50.72B
Weighted average by Cap.	-0.27%	-1.24%	-6.00%	-2.77%

	2017	2018
Net sales	20.15M 17.57M 16.27M 15.24M 28.57M 1.9B 28.75M 193M 74.83M 936M 75.65M 74.03M 3.25B	27.67M 24.13M 22.35M 20.92M 39.23M 2.61B 39.47M 265M 103M 1.29B 104M 102M 4.46B
Net income	-21.28M -18.55M -17.18M -16.08M -30.16M -2.01B -30.35M -204M -79M -988M -79.87M -78.15M -3.43B	-25.12M -21.9M -20.29M -18.99M -35.62M -2.37B -35.83M -241M -93.27M -1.17B -94.3M -92.28M -4.05B
Net Debt	-	-